Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
pKzTR7CxVkNhn9WG
